The US Food and Drug Administration (FDA) has approved a label expansion for ClaroNav’s dental navigation system, Navident EVO, to perform guided endodontic surgeries.
Navident uses volumetric medical images (CBCT) and real-time movement tracking to help dentists perform dental procedures, including placing implants. Endodontics is a dental procedure used to treat infection at the centre of a tooth, also known as a root canal.
The Navident EVO can provide minimally invasive access to tooth structures during root canals. The navigation allows dentists to preserve tooth structure and have less invasive access to calcified and hidden canals. The device also increases the overall efficiency of root canal procedures by saving time in locating and accessing canals.
GlobalData expects the is expected to increase from being worth approximately $19.7bn last year to more than $42.9bn by 2033. The dental imaging segment is forecasted to grow from $731m to $873m over the same period.
The Navident EVO system was developed as an improvement on ClaroNav’s Navident system, which is cleared by the FDA to perform multiple guided dental surgeries, including implant cases and endodontic procedures. The EVO system was commercially launched in March 2024.
Navident EVO has a dedicated endodontic mode which can help improve the ability of the clinician to effectively detect, diagnose, and plan treatment before dynamic navigation, as per ClaroNav. The device also used AI diagnostic tools to help perform dental surgeries.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe adoption of generative AI in the medical devices sector has been steadily increasing in the past few years. GobalData forecasts the AI market to reach sales of $93bn in 2023, an increase of 12% from 2022. Multiple companies are developing AI-powered imaging systems.
In February, Israel-based Magentiq Eye published data from a clinical trial showing that its AI-aided detection colonoscopy tool, Magentiq-Colo CADe increased adenoma detection by 7%, compared. Adenoma detection and removal is an important part of colorectal screening, with higher adenoma detection rates associated with a reduced risk of developing colorectal cancer.
